Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
149.22
+1.18 (0.80%)
At close: Dec 5, 2025, 4:00 PM EST
150.80
+1.58 (1.06%)
After-hours: Dec 5, 2025, 6:19 PM EST
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $170.99M in the quarter ending September 30, 2025, with 63.22% growth. This brings the company's revenue in the last twelve months to $561.26M, up 65.83% year-over-year. In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth.
Revenue (ttm)
$561.26M
Revenue Growth
+65.83%
P/S Ratio
13.09
Revenue / Employee
$821,761
Employees
683
Market Cap
7.52B
Revenue Chart
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
AXSM News
- 1 day ago - Axsome Therapeutics, Inc. (AXSM) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 4 days ago - 2 Under-the-Radar Stocks to Buy Heading Into 2026 - The Motley Fool
- 16 days ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 26 days ago - 2 Monster Stocks in the Making - The Motley Fool
- 4 weeks ago - Axsome Therapeutics Acquires Subtype Selective GABA-A Receptor Positive Allosteric Modulator AZD7325 for the Treatment of Epilepsy - GlobeNewsWire
- 4 weeks ago - Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics - GlobeNewsWire
- 4 weeks ago - Axsome: Alzheimer's Disease Agitation sNDA Adds Optionality, Not A Thesis Changer - Seeking Alpha
- 4 weeks ago - Axsome Therapeutics, Inc. (AXSM) Q3 2025 Earnings Call Transcript - Seeking Alpha